Advertisement

BMS phase III study didn’t meet primary endpoint of OS with Opdivo + radiation in glioblastoma multiforme

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bristol-Myers Squibb Co. said the phase III CheckMate-498 trial evaluating Opdivo (nivolumab) plus radiation vs. temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated glioblastoma multiforme did not meet its primary endpoint of overall survival at final analysis.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
Advertisement
Advertisement